(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.37%) $91.47
Live Chart Being Loaded With Signals
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins...
Stats | |
---|---|
Dagens volum | 2 011.00 |
Gjennomsnittsvolum | 3 316.00 |
Markedsverdi | 130.76M |
EPS | $0 ( 2024-03-14 ) |
Neste inntjeningsdato | ( $-0.970 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.930 |
ATR14 | $0.102 (2.56%) |
Molecular Partners AG Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
GTEC | 0.846 |
DRUG | 0.838 |
DLHC | 0.834 |
TACT | 0.831 |
SAGE | 0.83 |
APLS | 0.828 |
INTA | 0.824 |
AEI | 0.819 |
ZS | 0.817 |
TELA | 0.816 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Molecular Partners AG Økonomi
Annual | 2023 |
Omsetning: | $7.04M |
Bruttogevinst: | $-40.81M (-579.80 %) |
EPS: | $-1.890 |
FY | 2023 |
Omsetning: | $7.04M |
Bruttogevinst: | $-40.81M (-579.80 %) |
EPS: | $-1.890 |
FY | 2022 |
Omsetning: | $189.56M |
Bruttogevinst: | $138.81M (73.23 %) |
EPS: | $3.63 |
FY | 2021 |
Omsetning: | $9.33M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-2.06 |
Financial Reports:
No articles found.
Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.